Promises and limitations of nanoparticles in the era of cell therapy: Example with CD19-targeting chimeric antigen receptor (CAR)-modified T cells

Helene Jakobczyk (1) , Flavien Sciortino (2) , Soizic Chevance (2) , Fabienne Gauffre (2) , Marie-Bérengère Troadec (1)

1 IGDR - Institut de Génétique et Développement de Rennes
2 ISCR - Institut des Sciences Chimiques de Rennes

A number of nanoparticles has been developed by chemists for biomedical applications to meet imaging and targeting needs. In parallel, adoptive T therapy with chimeric antigen receptor engineered T cells (CART cells) has recently held great promise in B-cell malignancy treatments thanks to the development of anti-CD19 CAR T cells. Indeed, CD19 is a reliable B cell marker and a validated target protein for therapy. In this perspective article, we propose to discuss the advantages, limits and challenges of nanoparticles and CAR T cells, focusing on CD19 targeting objects: anti-CD19 nanoparticles and anti-CD19 CAR T cells, because those genetically-modified cells are the most widely developed in clinical setting. In the first part, we will introduce B cell malignancies and the CD19 surface marker. Then we will present the positioning of nanomedicine in the topic of B cell malignancy, before exposing CAR T technology. Finally, we will discuss the complementary approaches between nanoparticles and CAR T cells.

Keywords: B cell; CD19; Cell therapy; Chimeric antigen receptor; Nanoparticles; T cell

Domains: Chemical Sciences; Medicinal Chemistry; Life Sciences [q-bio]; Pharmaceutical sciences

Helene Jakobczyk, Flavien Sciortino, Soizic Chevance, Fabienne Gauffre, Marie-Bérengère Troadec. Promises and limitations of nanoparticles in the era of cell therapy: Example with CD19-targeting chimeric antigen receptor (CAR)-modified T cells. International Journal of Pharmaceutics, 2017, 532 (2), pp.813-824. ⟨10.1016/j.ijpharm.2017.07.075⟩. ⟨hal-01617055⟩